(Q57904741)

English

Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFα in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherap

article by Aristotelis Bamias et al published February 2008 in Gynecologic Oncology

In more languages

Statements

scholarly article

0 references

Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFα in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherap (English)

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

George Papatheodoridis

object named as

G. Papatheodoridis

11

0 references

Athanasios Dimopoulos

14

object named as

M.A. Dimopoulos

0 references

author name string

Aristotelis Bamias

1

0 references

Vasiliki Koutsoukou

2

0 references

Evangelos Terpos

3

0 references

Marinos L. Tsiatas

4

0 references

Christina Liakos

5

0 references

Ourania Tsitsilonis

6

0 references

Alexandros Rodolakis

7

0 references

Zannis Voulgaris

8

0 references

G. Vlahos

9

0 references

Theocharis Papageorgiou

10

0 references

A. Archimandritis

12

0 references

A. Antsaklis

13

0 references

language of work or name

0 references

publication date

February 2008

0 references

Gynecologic Oncology

0 references

108

0 references

2

0 references

421-427

0 references

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

Ovarian cancer: epidemiology, biology, and prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

Review article: immune suppression and colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

Regulatory T cells in ovarian cancer: biology and therapeutic potential

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

Expression of macrophage colony-stimulating factor (M-CSF), interleukin-6, (IL-6), interleukin-1 beta (IL-1 beta), interleukin-11 (IL-11) and tumour necrosis factor-alpha (TNF-alpha) in p53-characterised human ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

Vascular endothelial growth factor C gene expression is closely related to invasion phenotype in gynecological tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

Second-line treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

Dendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicobiological findings.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

Cytokine-induced Killer Cells: NK-like T Cells with Cytotolytic Specificity against Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

Myeloid progenitor cell regulatory effects of vascular endothelial cell growth factor

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

alpha1beta1 Integrin+ and regulatory Foxp3+ T cells constitute two functionally distinct human CD4+ T cell subsets oppositely modulated by TNFalpha blockade

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

Heat shock protein 60 enhances CD4+ CD25+ regulatory T cell function via innate TLR2 signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.10.018

7 January 2021

Identifiers

10.1016/J.YGYNO.2007.10.018

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57904741&oldid=1998200435"